ABSTRACT: Pulsatility seems to have a teleological role because evolutionary hierarchy favors higher ordered animals with more complex, multichamber circulatory systems that generate higher pulse pressure compared with lower ordered animals. Yet despite years of such natural selection, the modern generation of continuous-flow left ventricular assist devices (CF-LVADs) that have been increasingly used for the last decade have created a unique physiology characterized by a nonpulsatile, nonlaminar blood flow profile with the absence of the usual large elastic artery Windkessel effect during diastole. Although outcomes and durability have improved with CF-LVADs, patients supported with CF-LVADs have a high rate of complications that were not as frequently observed with older pulsatile devices, including gastrointestinal bleeding from arteriovenous malformations, pump thrombosis, and stroke. Given the apparent fundamental biological role of the pulse, the purpose of this review is to describe the normal physiology of ventricular-arterial coupling from pulsatile flow, the effects of heart failure on this physiology and the vasculature, and to examine the effects of nonpulsatile blood flow on the vascular system and potential role in complications seen with CF-LVAD therapy. Understanding these concomitant vascular changes with CF-LVADs may be a key step in improving patient outcomes as modulation of pulsatility and flow characteristics may serve as a novel, yet simple, therapy for reducing complications.
L eft ventricular assist devices (LVADs) are an increasingly used treatment option for patients with advanced heart failure (HF) refractory to medical therapy. The first-generation LVADs were designed as volume displacement pumps, similar to the native ventricle. These devices resulted in pulsatile flow (PF) that dramatically improved cardiac hemodynamics, yet had limited adoption in clinical practice because of their large size and limited mechanical durability. To decrease LVAD size and increase durability, there was a desire to minimize the number of moving parts and bearings. Specifically, the next generations of LVADs were engineered with either an axial flow pump where the internal rotor was suspended on a blood immersed bearing or a centrifugal-flow pump where the internal rotor was hydromagnetically levitated. Both of these LVAD designs have resulted in a dramatic increase in durability, reduction (but not elimination) in the number of complications, and improvement in patient survival. As a result, the current-generation continuous-flow (CF) LVADs are an increasingly common treatment option for end-stage HF and have replaced the first-generation PF-LVADs.
Individuals supported by CF-LVADs typically do not have a physiological pulse. The device itself provides circulatory support that is nonpulsatile (because of continuous rotation of the axial rotor or centrifugal-flow impeller), but as evidenced by pump speed modulationstudies, some degree of pulsatility exists because of contractile reserve of the native ventricle.
1,2 Specifically, at lower pump speeds, the aortic valve opens more frequently and pulsatility increases. Conversely, as higher pump speeds, an increasing amount of circulatory support is provided by the device and consequently, the aortic valve opens less often (or not at all), and the degree of pulsatility declines. This pulsatility can be assessed by arterial line, Doppler tracing, or finometers which use the Peñaz method.
1, 3 In addition, although outcomes have improved, patients supported with CF-LVADs have a unique set of complications that were not seen as frequently with PF-LVADs, including gastrointestinal bleeding, arteriovenous malformations, pump thrombosis, and stroke. 4, 5 Some of these complications have been postulated to be related to the unique flow patterns seen in CF-LVADs and resultant systemic sequela ( Figure  1 ) bringing to the forefront a fundamental question: Do humans need a pulse? In fact, there does seem to be an evolutionary hierarchy of sorts with higher ordered animals having more complex, multichamber circulatory systems that generate higher pulse pressure compared with lower ordered animals. 6 Given this apparent teleological role of pulse pressure and the removal of the pulse with the evolution of LVAD technology, the purpose of this review is to cover the normal physiology of ventricular-arterial (VA) coupling from PF, the effects of HF on this physiology and the vasculature, and to examine the effects of nonpulsatile blood flow on the vascular system and potential role toward complications seen with CF-LVAD therapy.
VA COUPLING AND THE ROLE OF PULSATILITY The Physiology of Normal Arterial Blood Flow
The debate on defining pulsatility has been ongoing for at least a half-century 7 and to date, there is no universal agreement on the definition of PF. From both a physiological and clinical standpoint, pulsatility is quantified by metrics such as pulse pressure (pulse pressure=systolic pressure−diastolic pressure) and the pulsatility index (pulsatility index=V max −V min /V mean ), where V max , V min , and V mean are the maximal, minimal, and average blood flow velocities, respectively, in an arterial bed. Terms such as pulse pressure and pulsatility index describe pulsatility through the framework of a pressure gradient. However, pulsatility may also be described or quantified by energy equivalent pressure 7 or surplus hemodynamic energy, which describe arterial perfusion by energy gradients generated from the cardiovascular system. Energy equivalent pressure is defined as the energy per unit of volume pumped and calculated as ∫ ∫ QPdt Qdt / , where Q and P are the instantaneous flow and pressure, and dt is the change in time. 7 Surplus hemodynamic energy is calculated as 1332×(EEP−MAP), where EEP is energy equivalent pressure; and MAP is the mean arterial pressure. 8 During ventricular contraction, a pressure gradient is generated between the ventricle and the aorta that allows blood to be transmitted to the arterial system. The pressure that is transmitted from the ventricle to the arterial system during systole comes from 2 sources. The first is the pressure transmitted from the velocity of blood flow in the arterial system, also known as wave motion. 9 The second component of aortic pressure comes from the increase in volume of blood that enters the aorta. When blood enters the aorta, the increased volume leads to arterial distention, which in turn reflects arterial compliance. During diastole, elastic recoil of the large arteries displaces blood into the periphery, ensuring that dependent tissue receives a continuous supply of oxygenated blood throughout the cardiac cycle. This phenomenon is termed the Windkessel effect (Figure 2 ), which is able to reduce ventricular afterload through the forward displacement of blood. Myocardial afterload, which is reflected in the myocardial wall stress needed to generate fiber shortening in ventricular systole, is intricately related to the time course of LV contraction such that peak myocardial wall stress occurs in early systole to protect myocardial cells from excessive afterload in mid-to-late systole and prevent LV remodeling. Poorly timed wave reflections, which are seen in stiffened arteries, increase late systolic LV afterload to make the heart more susceptible to the deleterious effects of increased afterload. 10 Interactions between the LV and arterial tree (VA coupling), commonly assessed by pressure-volume loops, describe ventricular energetics and provide insight into remodeling that occurs as part of the natural history of HF with reduced ejection fraction.
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HF with reduced ejection fraction is characterized by a high E A /E ES ratio (E A describes arterial elastance and E ES refers to LV end-systolic elastance), which results primarily from a reduction in E ES as a consequence of reduced pump function. 11 In the setting of LVAD support, the pressure-volume loop shifts leftward because of mechanical unloading. Furthermore, the loop takes on a triangular appearance as the ventricle is unloaded, because of reduction/elimination of isovolumic contraction and relaxation, 12 which explains why systemic flow, in the setting of CF-LVAD support, is essentially nonpulsatile. As the ventricle is loaded, the pressure-volume loop may take on a more traditional appearance, which would allow for restoration of pulsatility. In addition, E ES may increase 12 suggesting some improvement in VA coupling by a reduction in the E A /E ES ratio.
Sympathetic Regulation of the Cardiovascular System and the Role of Pulsatility
Arterial baroreceptors, located in the aortic arch and carotid sinus, are innervated by stretch-sensitive afferent nerve fibers that respond to fluctuations in arterial pressure and rhythmic deformation, as occurs with PF. When activated, these afferents connect to the brain stem, which then modulates sympathetic nerve activity (SNA) on a beat-to-beat basis through a negative feedback loop.
1 Thus, SNA in humans is modulated, to a large extent, by rhythmic pulsatile distension. This relationship between pulsatility and SNA has been demonstrated in animal models, 13, 14 but LVAD patients, with minimal or entirely nonpulsatile circulatory support, have provided new insights into arterial baroreceptor physiology in humans. For example, patients with CF-LVADs have markedly elevated levels of SNA compared with healthy individuals and advanced HF patients supported by the older, PF-LVADs. 15 Indeed, SNA levels among CF-LVAD patients in the supine position are greater than levels observed among healthy individuals who are upright. 15 This finding underscores an underappreciated observation about the impact of chronic exposure to non-PF on the human body, particularly as it relates to hypertension in these patients. Hypertension may be driven by these extremely high levels of SNA, which predisposes to adverse events such as stroke and progressive renal dysfunction. There is evidence to suggest that the restoration of PF (through LVAD pump speed modulations) may reduce SNA through baroreceptor recruitment, at least acutely.
1 There is interest in refining next-generation LVADs that enhance pulsatility. Additional investigation is necessary to determine whether this type of circulatory support is associated with improved baroreceptor sensitivity, as well as reduced levels of SNA and better control of blood pressure.
VA Coupling and Peripheral Adaptations in HF
It is well known that in HF, there is increased neurohormonal activation and sympathetic tone. This initial compensatory increase in sympathetic tone attempts to maintain cardiac output by increasing contractility and heart rate but also results in increased arterial and venous tone to maintain blood pressure. In the periphery, this increase in vasoconstriction contributes to impaired vasodilatory reserve and capillary recruitment during exercise when muscle metabolic demand increases. This ultimately leads to underperfusion, ischemia, release of reactive oxygen species, and chronic inflammation in skeletal muscle and contributes to the early transition to anaerobic metabolism commonly seen in patients with advanced HF.
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VASCULAR ADAPTATIONS TO NON-PF Early Investigations of Nonpulsatile Cardiopulmonary Bypass
Innovations in the development of cardiopulmonary bypass led to the earliest studies of the unique physiology of non-PF. As early as the 1960s, investigators demonstrated that canines exposed to short-term non-PF versus PF had increases in peripheral vascular resistance thought to be the result of baroreceptor-mediated increased vascular tone. 17 Further investigations in the 1970s elucidated a potential mechanism for such increases in peripheral vascular resistance because sympathetic activity and plasma angiotensin II levels were significantly elevated in nonpulsatile states. 18 Indeed, similar observations were noted in patients undergoing cardiopulmonary bypass, where plasma norepinephrine levels increased after exposure to nonpulsatile bypass, but such catecholamine increases were not observed in patients receiving pulsatile bypass. 19 Finally, studies of goats exposed to 4 weeks of nonpulsatile left heart bypass demonstrated that the vasoconstrictive response to norepinephrine was blunted after chronic exposure to non-PF. 20 This blunted vasoconstrictive response may have been related to downregulation of adrenergic receptors with chronic exposure to non-PF. Another possible mechanism for the blunted vasoconstrictive response may be related to A, Healthy patient: in normal physiology, the aorta acts a reservoir to store 50% of the stroke volume during systole. In diastole, elastic recoil pushes the stored volume of blood to the peripheral vasculature to maintain continuous perfusion of the periphery throughout the cardiac cycle. The aortic pressure waveform has pressure on the y axis and time on the x axis. The dicrotic notch (arrow) signals the end of systole and beginning of diastole. The slope of the aortic upslope reflects myocardial contractility. The slope of the diastolic waveform is a reflection of aortic compliance and the area under the diastolic portion is a measure of coronary blood flow. B, Patient with vascular disease: in conditions that increase arterial stiffness such as aging or atherosclerosis, the aorta is less compliant of blood volume. This decrease in vessel elasticity results in decreased storage of stroke volume in the aorta, increased forward flow in systole, and increased systolic blood pressure (*). In diastole (arrow signifies the dicrotic notch), the slope of the pressure waveform shows a steeper decline as a result of this decrease in stored volume within the stiff vessel resulting in a lower diastolic pressure. The resultant wide pulse pressure is a commonly observed marker of vascular stiffness. C, Patient with a continuous-flow left ventricular assist device (CF-LVAD): the interactions between stroke volume and vessel compliance with CF-LVAD are challenging to assess, in large part, because of the lack of a true systole and diastole with nonpulsatile flow. In addition, the flow from the CF-LVAD outflow graft in the ascending aorta may influence the fluid dynamics within more distal portions of the vessel. It is known that CF-LVAD therapy is associated with increased aortic stiffness and aortic dilation, but the systemic effects of these changes remain under active investigation. changes in vascular smooth muscle. These same investigators noted that there were morphological changes in the aortic wall with vessel thinning and smooth muscle atrophy after a longer exposure (≈4 months) of nonpulsatile left heart bypass. 21 Taken together, these studies suggest that there are both acute and chronic vascular effects that result from non-PF and that these effects may partially be the result of baroreceptor-mediated sympathetic activation and alterations in the vascular smooth muscle.
Aortic Valve and Aortic Vascular Changes With CF-LVADs
Shortly after the adoption of CF-LVAD therapy, it was noted that the most proximal portions of the vascular system-the aortic valve and aorta-were susceptible to unique changes that were not observed in patients with PF-LVADs. The developments of de novo as well as worsening of existing aortic valvular regurgitation are known complications of CF-LVAD therapy. 22 The postulated mechanisms for the progression of aortic regurgitation with CF-LVAD therapy include the lack of aortic valve opening leading to commissural fusion with myxomatous degeneration of the aortic valve leaflets. 23 On a cellular level, the altered dynamics of continuous flow increase macrophage response with valvular interstitial cells becoming activated and more numerous, leading to remodeling of the ventricular layer of the aortic valve. 24 Moreover, large-scale protein profiling from aortic valves from LVAD patients have shown upregulation of proteins involved with TGF (transforming growth factor)-β, a protein involved in several valve diseases, including myxomatous mitral valve disease and aortic stenosis. 25 Aortic valve injury may also develop from increased shear stress because of retrograde flow into the aortic root. The incidence of aortic regurgitation is less among individuals with intermittent aortic valve opening because commissural fusion is not possible when valve leaflets are in motion. 23, 26 Remodeling within the aortic root and proximal ascending aorta may also contribute toward the pathophysiology of aortic regurgitation with CV-LVAD. Studies have demonstrated that the proximal aorta dilates after chronic CF-LVAD support and that increasing aortic diameter was associated with the development of aortic regurgitation. 27 It is also possible that CF-LVADs contribute to the development of an aortopathy through adverse effects on the aortic wall. In a study comparing post-transplant patients who had no LVAD, a CF-LVAD, or a PF-LVAD before transplantation, we found that patients with CF-LVADs before transplant had a dramatic increase in proximal aortic stiffness compared with patients without a LVAD or with PF-LVADs before transplant. 28 Remarkably, this increase in aortic stiffness immediately after transplant was significantly attenuated a year after transplant with restoration of normal PF. These findings suggest there is potential for dynamic remodeling within the aorta as a result of alterations in blood flow patterns.
The in vivo findings of increased aortic stiffness have also been confirmed with in vitro testing of aortic wall tissue samples collected at the time of transplant. We performed biomechanical stress-strain testing of aortic tissue from patients with HF with and without a CF-LVAD before transplant and compared these with nonfailing donor aortic tissue. The vessel physiological modulus, a direct measure of vascular stiffness as this is the elastic modulus at physiological blood pressure, was significantly higher in the aortic samples from patients with CF-LVADs before transplant compared with patients with HF without a CF-LVAD and nonfailing donors. Furthermore, there was evidence of structural remodeling within the aortas of CF-LVAD patients including an increase in total wall thickness, an increase in collagen content, and a reduction in elastin content that could explain the increase in vessel stiffness. 29 Two additional studies have also reported a reduction in the number of elastin fibers after LVAD support. 30, 31 These studies were also notable for a decrease in the number of smooth muscle cells within the vessel media and atrophy of media layer. Whether such changes are related to alterations in flow profiles from CF-LVAD versus systemic factors remain unknown. Interestingly, in an animal study of sheep implanted with CFLVADs, investigators similarly observed a reduction of the medial layer of the ascending aorta with non-PF. 32 This medial atrophy with non-PF was accompanied by a significant increase in plasma renin levels, suggesting a potential contributory role of the renin-angiotensinaldosterone system in the vascular remodeling seen with CF-LVADs.
Cerebrovascular Perfusion With CF-LVADs and the Role of Autonomic Regulation
Cerebral autoregulation is a multifaceted process that depends on proper functioning of vascular/myogenic and neurogenic components. The vascular component refers to adjustments in blood vessel diameter that occur in response to fluctuations in intraluminal pressures and release of endogenous vasoactive substances such as nitric oxide. 33 The neurogenic arm refers to adjustments in the tone of cerebral resistance vessels occurring in response to supply-demand mismatch of oxygen and glucose. 34 Given that CF-LVAD patients have marked increases in SNA through baroreceptor unloading, there was concern that autoregulatory processes would be impaired in the setting of non-PF because of abnormally high tonicity of resistance vessels. However, autoregulatory indices for CF-LVAD patients are similar to levels observed among healthy individuals and those with previous-generation PF-LVADs, suggesting that cerebral autoregulation is preserved in the midst of nonpulsatile cerebral perfusion. 3 Although there is ongoing investigation to advance the understanding of autoregulatory processes in the human body, this finding suggests that the brain preserves the ability to control perfusion despite marked increases in SNA that would otherwise work to increase tonicity of cerebral resistance vessels. Because neurological events and strokes are common and among the most devastating complication of CF-LVAD therapy, a better understanding of cerebrovascular perfusion with non-PF is critical.
CF Effects on End Organ and Peripheral Vessels
The initial clinical trials in CF-LVADs showed dramatic improvements in cardiac output and hemodynamics that resulted in stability or improvement in end-organ perfusion immediately post-implant. For example, in a retrospective analysis of 83 patients who underwent CF-LVAD implantation, renal function improved at 1, 3, and 6 months post-implant. 35 However, these initial clinical improvements may not be sustained. In an analysis of renal function from 3363 patients with LVAD enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support, renal function improved in only 6.7% of patients after 1 year of follow-up. 36 Interestingly, this finding was consistent in both PFLVADs and CF-LVADs, suggesting that factors beyond pulsatility may be contributing to renal dysfunction after LVAD implantation.
The potential influence of LVAD placement on endorgan vasculature does deserve further attention. In a study of CF-LVADs implantation into calves, the overwhelming majority of calves developed smooth muscle hypertrophy along with interstitial inflammatory infiltration surrounding the vessel walls of the renal cortex arteries. 37 A similar study confirmed the development of severe periarteritis after CF-LVAD implantation and noted that the local renin-angiotensin system was upregulated in the inflammatory cell infiltrate. 38 Unfortunately, little is known about the effects of chronic non-PF on peripheral vessels among patients receiving CF-LVAD support. In a small postmortem study of 16 CF-LVAD and 9 PF-LVAD patients, a histological analysis of tissue from liver, kidney, coronary arteries, and brain vessels did not reveal any obvious differences in arterial wall characteristics between the 2 groups. 39 However, the median duration of CF-LVAD support was only 263 days and the patients received a variety of different types of both PF and CF devices with varying implant configurations. By contrast, preliminary results from our laboratory suggest that CF-LVAD support may be associated with coronary artery remodeling and fibrosis. 40, 41 In normal physiology, coronary filling occurs predominantly in diastole when LV pressures are lower and the coronary arteries are more dilated. With CF-LVAD support, LV pressures should be lower, but there is no clear mechanical systole and diastole. The blood flow patterns within the proximal aorta and aortic root may also be altered from the LVAD outflow graft. In a study of coronary artery vessel samples collected at the time of transplantation, coronaries from patients supported with CF-LVAD before transplant had evidence of expansion of the adventitia, breakdown of the internal elastic lamina, thickening of the external elastic lamina, and increased adventitial collagen deposition with increased vasa vasorum density compared with vessels of patients with HF without a CF-LVAD and nonfailing donors. 40 The contribution of such fibrotic changes in the coronary arteries toward myocardial ischemia and CF-LVAD complications such as ventricular arrhythmias and right ventricular failure warrants additional investigation. Furthermore, there is clear evidence of remodeling within the more distal arterioles with CF-LVAD support. Gastrointestinal bleeding, particularly from arteriovenous malformations, is a common complication with CF-LVAD therapy with rates out of proportion than what can be accounted for with anticoagulation and antiplatelet therapy alone. 42 Recent data suggest that the mucosal arteriovenous malformations within the gastrointestinal tract may in fact reflect a systemic phenomenon because investigators found a greater amount and severity of nasal hypervascularity within the intranasal cavity of patients with CF-LVAD with a history of gastrointestinal bleeding. 43 
CF-LVADs Effects on Endothelial Cell Function and Microcirculation
In addition to the effects of CF-LVADs on the vessels themselves, there is mounting evidence that this unique physiology of flow may affect endothelial cell function with subsequent systemic effects. In an animal model, higher levels of matrix metalloproteinase activity and markers of cellular proliferation were observed as the pulsatility was experimentally decreased, suggesting that matrix degradation may contribute to the pathophysiology of increased vascular resistance with non-PF. 44 In another animal study using a centrifugal-flow LVAD, the systemic vascular resistance increased and circulating nitric oxide levels decreased with diminishing pulsatility. 45 Additional animal studies have found similar reductions in endothelial nitric oxide production with non-PF accompanied by an increase in measures of reactive oxygen species, suggesting that non-PF may cause inflammatory damage to the endothelial cells which may adversely affect their function. 46, 47 Some of the findings from animals have also been observed in patients exposed to non-PF. In a study of CF-LVADs versus PF-LVADs, there was a greater increase in the circulating levels of some inflammatory cytokines and markers of complement activation with the CF-LVADs. 48 Similarly, histological comparisons of aortic tissue before and after LVAD implantation have demonstrated evidence of vascular inflammation with increased expression of vascular adhesion molecules after CF-LVAD placement. 49 Such findings of an inflammatory response as well as increased expression of antioxidant genes have also been observed in human aortic endothelial cells cultured in vitro and exposed to non-PF to replicate CF-LVAD support. 50 Studies in patients using peripheral flow-mediated dilation as an assessment of endothelial cell dysfunction have also found a correlation with reductions in pulsatility being associated with greater endothelial cell dysfunction. 51, 52 In addition, patients with PF-LVAD had less endothelial cell dysfunction than those with CF-LVAD. 53 Furthermore, there is evidence that endothelial cell dysfunction may be reversible with restoration of pulsatility because flow-mediated dilation improved after pulsatility was restored after cardiac transplantation. In this study, endothelial cell dysfunction was also directly correlated with plasma free hemoglobin levels, suggesting that the hemolysis from CF-LVADs may impair red blood cell nitric oxide scavenging abilities and contribute to endothelial dysfunction and inflammation. 52 The potential implications of a link between diminished pulsatility, inflammation, hemolysis, and endothelial dysfunction to the pathophysiology of LVAD pump thrombosis warrants additional investigation.
Beyond Pulsatility: Alterations in Flow Dynamics From CF-LVAD Outflow Graft
The unique blood flow profiles generated from CFLVADs are considerably more complex than simply flow with no pulse. The LVAD outflow graft anastomosis results in an altered flow profile. The normal laminar flow of blood through the aortic valve and into the ascending aorta is replaced instead with turbulent jet out of an outflow graft on the anterolateral aspect of the aorta. It is certainly possible that some of the vascular changes described above may in fact be related to this unique alteration of flow rather than simply non-PF. The clinical implications of such alterations in flow warrant further investigation because variables such as the angle, orientation, degree of torsion, and location of the LVAD outflow graft are relatively easy to manipulate at the time of LVAD implantation if there were a therapeutic benefit.
Indeed, a recent computational dynamic modeling study based on reconstructions of the aorta from computed tomographic scans demonstrated that slight manipulations of the anastomosis angle and the amount of torsion of the outflow graft resulted in significant differences of the velocity and kinetic energy profiles for flow within the thoracic aorta. 54 In addition, another group of investigators used computational fluid dynamics models to evaluate for differences in shear stress within the branches of the celiac artery based on the anatomic takeoff angulation of the vessel from the aorta along with the LVAD pump speed as a potential assessment of gastrointestinal bleeding risk. 55 Further evidence of the potential clinical relevance of such investigations involving LVAD fluid dynamics comes from studies where the location of the outflow graft anastomosis was not in the ascending aorta. For example, in a small study of patients with CF-LVAD where the outflow graft anastomosis was in the descending thoracic aorta, serial annual computed tomographic scans out to 6 years revealed no changes in aortic diameter, despite this long duration of support. 30 This is in stark contrast to the aortic dilation observed with chronic CF-LVAD support when the outflow graft anastomosis is in the ascending aorta. The most compelling data on the optimal angle of the outflow graft relative to the aorta date from 2004 56 and suggest that an angle of 30° results in minimal shear stress on the aortic wall. However, most current recommendations are for an outflow angle of 45° to 60°, although no clear evidence exists to support this recommendation. Additional research on optimizing the location and orientation of the outflow graft to improve clinical outcomes is needed.
ADDITIONAL CLINICAL IMPLICATIONS OF CF-LVAD-RELATED VASCULAR CHANGES Exercise Intolerance in Patients With CFLVADs
Despite marked improvements in New York Heart Association functional classification, functional capacity, as measured by peak oxygen uptake (Vo 2 ), remains severely limited, with values generally in the range of 12 to 15 mL kg −1 min −1
. [57] [58] [59] This discrepancy between New York Heart Association status and peak Vo 2 has generated great interest in understanding the physiology of exercise during CF-LVAD support and although further research is necessary, there are several potential causes to explain the persistent reduction in functional capacity: (1) fixed pump speed with limited ability to augment flow in the setting of increased venous return during exercise, (2) ventilation/perfusion mismatch, (3) skeletal muscle atrophy, (4) impaired vasodilatory reserve, and (5) reduced oxygen extraction capacity. [60] [61] [62] The preload sensitivity of CF-LVADs currently in use is lower than the normal heart. 63 Thus, despite an increase in venous return that occurs during exercise, the ability of the pump to augment flow is limited com-pared with the normal heart. There has been interest in modulating pump speed with exercise to increase CF-LVAD flow in an effort to facilitate delivery of oxygenated blood to the periphery and improve functional capacity. However, the results have been underwhelming, with no improvement in peak cardiac output or leg blood flow, 64 and little to no difference in exercise time or peak Vo 2 . 62, 65 One pump, still under investigational use and not approved by the Food and Drug Agency for clinical use (the Jarvik 2000), allows patients to manually adjust LVAD flow rate in anticipation of exercise; however, further data are necessary to determine whether this feature, unique to the Jarvik 2000, improves functional capacity.
Although a detailed review of the skeletal muscle abnormalities in advanced HF with reduced ejection fraction is beyond the scope of this article, the persistence of these abnormalities after CF-LVAD implantation also limits functional capacity irrespective of cardiac output/pump flow during exercise. Specifically, these patients have skeletal muscle atrophy with less recruitable muscle to perform work, impaired vasodilatory reserve, a relative increase in anaerobic (fasttwitch) muscle fibers in comparison with oxidative (slow-twitch) fibers, and limited convective and diffuse components of the oxygen cascade. 66 Although it has been demonstrated that cardiac rehabilitation leads to nominal improvements in Vo 2 , 67 future research is warranted to determine optimal methods to improve functional capacity after CF-LVAD implantation (eg, through pump speed modulations or exercise).
Myocardial Recovery With CF-LVADs and Implications of an Afterload Mismatch
Myocardial recovery through the use of LVADs as a bridge to recovery has been the Holy Grail for many investigators in the field, yet to date has resulted in exceedingly low rates of sufficient and sustained recovery to allow for successful LVAD explantation. 68 There is some evidence to suggest that myocardial recovery can more likely be achieved in PF versus CF devices. In a study of 387 patients with LVAD with idiopathic dilated cardiomyopathy, patients with PF-LVAD had an almost 3× higher chance of myocardial recovery and explant compared with patients with CF-LVAD. 69 Although the mechanism accounting for higher observed rates of recovery with pulsatile devices is unclear, it has been previously found that higher wall ventricular wall stress during late systole is associated with atrial dysfunction 70 and impaired systolic function and diastolic relaxation. 71 Pulsatile unloading of the heart by previousgeneration devices reduces wall stress in late systole compared with early systole, as compared with continuous-unloading provided by current-generation devices. This temporal change in wall stress may promote an environment that is favorable for recovery. In addition, there is a greater degree of LV unloading with subsequent improvements in neurohormonal activation with PF-LVADs compared with CF-LVADs. 72, 73 Another potential explanation is that LV afterload is substantially higher with CF-LVADs than with PF-LVADs. Contributors to increased afterload with CF-LVAD include a hyperadrenergic state with excess sympathetic tone, increased flow throughout the entirety of the cardiac cycle (including diastole), raising mean arterial pressures, and aortic stiffening with an upward/leftward shift in the aortic stress-strain curve. Another contributing factor to the low rate of myocardial recovery may be the structural changes within the coronary arteries that occur with CF-LVADs. 40, 41 If coronary flow reserve is restricted as a result of fibrotic changes within the vessels, this may result in insufficient myocardial oxygen supply for increased demands when the CF-LVAD is turned down or explanted.
There is great interest in determining whether temporary hemodynamic unloading of the ventricle through increased pump speed promotes an environment favorable for ventricular recovery and device explantation. Because blood pressure rises as pump speed is increased, 1 patients can theoretically tolerate higher doses of HF with reduced ejection fraction guideline-directed medical therapy. This strategy is currently being tested in the RESTAGE-HF (The Remission From Stage D Heart Failure) clinical trial.
Modulation of Pulsatility as a Therapeutic Intervention to Reduce CF-LVAD Complications
Minimization of CF-LVAD-related complications is of paramount importance to improving patient outcomes and reducing the cost of this therapy. As has been covered in this review, many of the common CF-LVAD complications may relate to the unique blood flow characteristics of these devices (Table) . A better understanding of this pathophysiology is needed, as modulation of flow dynamics and pulsatility are variables that can be controlled with current and future devices. Indeed, latest CF-LVADs have begun to incorporate a small amount of pulsatility in their design. The HeartWare Ventricular Assist System has the Lavare Cycle feature that provides periodic alterations in pump speed for intermittent opening of the aortic valve to promote washing of the aortic root and induce PF. 75 The Lavare Cycle is not available in the United States, but is commonly used in Europe and Australia where the reported rate of stroke is less than in the United States, and there was a suggestion of less adverse events among patients managed with the Lavare Cycle turned on. 74 Also, the lack of aortic valve opening in patients with HeartWare Ventricular Assist System was found to be a risk factor for arteriovenous malformations and subsequent gastrointestinal bleeding. 76 In addition, the HeartMate III incorporates automated modulations in pump speed, which serves to wash the aortic valve and prevent pump thrombosis. Notably, these pump speed modulations are not gated to the cardiac cycle and as such, do not coincide with or contribute to opening and closing of the aortic valve. Thus, whether these modulations in pump speed translate to any meaningful pulse is unclear and warrants further investigation.
CONCLUSIONS
The blood flow from the current generation of CF-LVADs is a unique physiological condition created by technological improvements in pump technology. Indeed, CF circulatory support is minimally/entirely nonpulsatile, characterized by a nonlaminar flow profile with complete absence of an aortic Windkessel effect. Understanding the concomitant vascular changes related to variations in physiological blood flow may be a key mediator toward understanding common CF-LVAD complications such as gastrointestinal bleeding, hypertension, stroke, and pump thrombosis. In addition, modulating flow characteristics may have a therapeutic role in improving patient outcomes with CF-LVADs. Future studies with standardized medical regimens that specifically assess different LVAD therapies, and the degree of pulsatility with close evaluation of cellular and physiological changes to various interventions, will be needed to further elucidate the beneficial effects of pulsatility. An effort is now being made with third-generation LVADs to induce pulsatility in CF-LVAD therapy, although it is unclear whether automated modulations in pump speed translate into a physiological pulse. Longer term followup will be needed to assess whether added pulsatility to CF-LVAD therapy can produce meaningful improvement in clinical outcomes while building on the efficiency, durability, and longevity of CF devices. 
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